舒利迭联合孟鲁司特钠治疗支气管哮喘的临床研究

Combination therapy with seretide and montelukast sodium in the treatment of bronchial asthma

目的观察舒利迭联合孟鲁司特钠治疗支气管哮喘的临床疗效。方法选取我院自2008年3月-2011年6月收入治疗的68例支气管患者，单盲随机分为对照组和治疗组；对照组32例支气管患者单纯吸入舒利迭治疗，治疗组36例患者在吸入舒利迭治疗的基础上口服孟鲁司特钠进行联合治疗。治疗3个月后，观察比较两组患者的肺功能情况和哮喘控制评分（ACT评分）。结果治疗组患者的肺功能水平和ACT评分[（25．02±1．97）分VS（19．96±2．01）分]均高于对照组患者（P〈0．05），两组患者在治疗过程均未见明显的不良反应。结论舒利迭联合孟鲁司特钠治疗支气管哮喘的临床效果显著，且无明显不良反应，值得临床推广应用。

Objective To observe the clinical efficacy of seretide combined with montelukast sodium in the treatment of bronchial asthma. Methods 68 patients with bronchial asthma who had been hospitalized during the period of March 2008 to June 2011 were randomly assigned to receive inhaled seretide alone （ 32 patients, control group ）, or oral montelukast sodium combined with inhaled seretide （ 36 patients, study group ）. 3 months after treatment, lung function and the Asthma Control Test （ ACT ） score were compared between the two groups. Results Lung function level and the ACT score were higher in the study group than in the control group [ACT score： （ 25.02 ±1.97 ） vs. （ 19.96 ±2.01 ）, P 〈 0.05]. No significant adverse reactions were found in all the patients during treatment. Conclusions Seretide combined with moutelukast sodium for bronchial asthma is efficacious and has no marked adverse reactions. It is worth popularizing clinically.